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Abstract: The HOX genes are a group of homeodomain-containing transcription factors that play
important regulatory roles in early development, including the establishment of cell and tissue
identity. HOX expression is generally reduced in adult cells but is frequently re-established as an
early event in tumour formation and supports an oncogenic phenotype. HOX transcription factors
are also involved in cell cycle regulation and DNA repair, along with normal adult physiological
process including stem cell renewal. There have been extensive studies on the mechanism by which
HOX proteins regulate transcription, with particular emphasis on their interaction with cofactors
such as Pre-B-cell Leukaemia Homeobox (PBX) and Myeloid Ecotropic Viral Integration Site 1 (MEIS).
However, significantly less is known of how the activity of HOX proteins is regulated. There is
growing evidence that phosphorylation may play an important role in this context, and in this
review, we draw together a number of important studies published over the last 20 years, and discuss
the relevance of phosphorylation in the regulation and function of HOX proteins in development,
evolution, cell cycle regulation, and cancer.
Keywords: HOX; phosphorylation; embryonic patterning; cell cycle; cancer
1. Introduction
The HOX genes encode a family of homeodomain-containing transcription factors that play
important roles in the early embryo, including the establishment of cell and tissue identity, and the
regulation of cell proliferation, differentiation, and survival [1]. A characteristic feature of this gene family
is their organisation within four clusters, each of which is located on a different chromosome. These
clusters, A, B, C, and D, are used in the nomenclature of HOX genes, which are also numbered according
to their relative position in the cluster, with, for example, HOXB1 being the most 3’ member of the B
cluster [2]. Despite being originally characterised as developmental genes, the HOX transcription factors
are known to have additional roles in the adult, including, for example, the proliferation of hematopoietic
stem cells (HSCs) [3], and the maintenance of tissue identity during the menstrual cycle [4].
The highly conserved homeodomain of HOX proteins mediates their binding to DNA, although
the strength and specificity of this interaction is greatly increased by the binding of co-factors such
as Pre-B-cell Leukaemia Homeobox (PBX), which forms heterodimers with HOX proteins in groups
1-10, and Myeloid Ecotropic Viral Integration Site 1 Homolog (MEIS) proteins that dimerize with
HOX proteins 9–13 [5]. These cofactors have a role in in the recruitment of RNA polymerase II or
III, as well as transcriptional inhibitors such as histone deacetylase (HDAC), resulting in differential
gene regulation depending on the sequence and context of the target site in the enhancer or promoter
region [6,7].
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Many of the HOX genes are also highly over-expressed in a range of cancers including
melanoma [8], and head and neck [9], prostate [10], breast [11], ovarian [12], and pancreatic cancer [13].
In this context they usually have a pro-oncogenic role, supporting a malignant phenotype. The latter
includes promoting proliferation and blocking apoptosis [14], the induction of angiogenesis [15],
and facilitating metastasis [16], drug resistance [11,17,18], and radiation resistance [19]. The key roles
that HOX proteins play in cancer make them potential therapeutic targets, although a high level of
functional redundancy amongst HOX proteins presents a barrier to this approach. An alternative
strategy is to inhibit the interaction between HOX and PBX, which is mediated by a conserved
hexapeptide sequence in HOX proteins. This interaction can be inhibited using HXR9, a small peptide
mimic of the hexapeptide sequence that causes apoptosis in a range of cancers [20].
Given the profound homeotic activity of HOX genes and their ability to influence processes in
the adult, including DNA repair and cell cycle regulation, there is relatively little known of how HOX
activity is itself regulated. Regulation occurs at the level of transcription in a process that is influenced
by enhancer sharing as well as epigenetic changes and signalling through a range of pathways,
most notably retinoic acid [1]. There have also been many studies of the role played by HOX co-factors
such as PBX and MEIS [20]. However, relatively little is known of how HOX transcription factors are
regulated at the post-translational level, despite HOX proteins containing multiple consensus sites
for a range of kinases (Figure 1). There was a recent, excellent review on HOX post-translational
modifications, which included phosphorylation [21]. Here, however, we focus on what is currently
known about HOX protein phosphorylation with special emphasis on its functional consequences in
development, cancer, and cell-cycle regulation.
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Figure 1. Consensus kinase sites in HOXB4 and HOXB7. The relative positions of the conserved
hexapeptide domain (“HEX”) that mediates Pre-B-cell Leukaemia Homeobox (PBX) binding and
the homeodomain (“HD”) that mediates DNA binding are shown. ATM, kinase mutated in ataxia
telangiectasia; ATR, ataxia telangiectasia and Rad3-related protein; CK2, casein kinase 2; CDK,
cyclin-dependent kinase; CLK, CDC2-like kinase; MAP3K19, mitogen-activated protein kinase kinase
kinase 19 (also known as RCK and YSK); PKA, protein kinase A; PKC, protein kinase C; SLK, STE-20 like
serine/threonine protein kinase.
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2. Kinase Regulation of HOX Proteins in Development and Evolution
As discussed above, the HOX genes play a key role in the patterning of both the vertebrate and
invertebrate body plan. In the latter, there is growing evidence that variations in HOX proteins might
have helped drive evolutionary changes in the morphology and number of appendages. A particularly
well-studied example is the change in the Ultrabithorax (UBX) protein that increased its ability to block
transcription of Distal-less (Dll), a gene that also encodes a homeodomain-containing transcription
factor. Dll is required for the development of appendages along with other embryonic structures,
but the change in UBX function to a transcriptional repressor of Dll is considered to have driven a
key change in the body plan of invertebrates, away from a uniform pattern of segments each bearing
a limb (as typified by the centipedes), to a more complex body plan exhibited by most insects [22].
This change in UBX function may have been mediated by the loss of serine and threonine residues at
casein kinase 2 (CK2) phosphorylation sites; the sites are present in invertebrates that have uniform Dll
expression, but absent in those that lack Dll expression in UBX expressing cells (Figure 2). Furthermore,
reintroducing CK2 phosphorylation sites in Drosophila UBX prevents it from repressing Dll, resulting
in embryos that show signs of multiple limb development [23]. The phosphorylation of UBX may,
therefore, play a key role in the repression of Dll expression and hence limb development in the
abdomen. Subsequent studies have revealed CK2 phosphorylation to also regulate the transcriptional
activity of other homeodomain-containing transcription factors including Engrailed-2 (EN2) [24]
and Antennapedia (ANTP) [25]. CK2 phosphorylation of the EN2 homeodomain increases its DNA
binding affinity 2–4-fold [24], whilst in the case of ANTP, it prevents binding to the extradenticle
(EXD) cofactor and thus reduces its activity [25]. Changes to ANTP that prevent CK2 phosphorylation
severely perturb thoracic and abdominal development, suggesting that it is no longer phenotypically
suppressed by more posterior HOX genes. Conversely, acidic amino acid substitutions at the CK2
target site (mimicking a constitutively phosphorylated ANTP protein), greatly reduce its in vivo
activity. Hence, as with UBX, CK2 phosphorylation plays a key role in modifying the ability of this
homeoprotein to affect embryonic development [25].
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Figure 2. Casein kinase 2 (CK2) phosphorylation is a key regulator of Ultrabithorax (UBX) function.
Phosphorylation of UBX by CK2 prevents it fro repressing Ditsal-less (Dll) transcription in lo er
arthropods and consequently all embryonic segments posterior to the head give rise to limbs. This CK2
site is lost in insects and as a result UBX represses Dll expression, leading to the suppression of limb
formation in the abdominal segments.
CK2 consensus sites are also present in many vertebrate HOX proteins, indicating that these
may also be regulated by CK2 as part of a developmental pathway (Figure 3). This is supported by
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the finding that the CK2 sites in HOXB7 are potential modifiers of its regulatory activity during the
proliferation and differentiation of primary hematopoietic cells [26]. Mutations in the CK2 sites located
in the first 14 amino acids of the C-terminal domain of HOXB7 enhanced the differentiation of the
murine myelomonocytic cell line, 32D, which concurs with reports that CK2 can act as an oncogene
when transfected into a number of normal mouse cell types (discussed in greater detail below) [27,28].
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Phos l i also plays a key role in the regulation f another Drosophila HOX gene,
sex combs reduced (SCR), which determines the identity of the labial and prothoracic egments.
A tudy based on east two-hyb id screening revealed th t the N-terminal arm within the
homeod main was a target of phosphorylation by cAMP-dependent protein kinase A (PKA) and
dephosphorylation by protein phosphatase 2A, with t e later activating and the former inactivating
SCR function in vivo, through the modulation of DNA binding. Correspondingly, knockdown of the
dPP2A,B’ gene encoding protein phosphatase 2A prevented salivary gland development, mimicking
the SCR null phenotype [30].
An additional example of phosphorylation regulating HOX function is provided by the role of
Abd-B in the induction of posterior spiracle organogenesis in Drosophila [31]. In the early stages
of this process, Abd-B activates multiple downstream targets including the Janus Kinase/Signal
Transducer and Activator of Transcription proteins (JAK/STAT) signalling pathway. However, at later
stages, STAT activity feeds back directly into Abd-B, increasing its ability to activate transcription of
downstream genes, whilst also acting to block the activity of other repressor proteins that inhibit the
function of these target genes. Thus Abd-B/STAT signaling forms a cooperative loop to maintain a
stable pattern of gene expression required for spiracle formation.
Phosphorylation is also an important regulator of the Caenorhabditis elegans HOX gene lin-39,
a homologue of the ANTP gene of Drosophila and the HOX paralogues in vertebrates [32], which acts
as a determinant of whether the epithelial Pn.p cells adopt a vulval precursor cell fate or fuse with the
surrounding hypodermis (the F fate). In this context, the vulval fate is determined by lin-39 activity
Cancers 2019, 11, 508 5 of 9
that, in turn, is enhanced through let-23 (receptor tyrosine kinase)/let-60 (Ras homologue) signalling,
most likely leading to direct phosphorylation of lin-39 by MAPK [33].
3. Kinase Regulation of HOX Proteins during the Cell Cycle
In addition to a role in development and disease, there is growing evidence that HOX proteins
play a role in regulating the cell cycle, and that they, in turn, can be regulated by cell-cycle dependent
activities. One of the best-characterised examples of the former is the inhibition of HOXC10
transcriptional activity through binding of its homeodomain by the cell-cycle regulator Geminin [34].
Structural studies revealed that the homeodomain of HOXC10 binds to Geminin, an interaction that is
mediated through the C-terminus of the latter in which the side chains of glutamates and aspartates
generate an overall charge pattern similar to the DNA phosphate backbone. This interaction with
Geminin is specific to HOXC10 as it is dependent on residues R43 and M54 in helix III, as well as
a cluster of basic amino acids in the N terminus. The strength of the interaction between Geminin
and HOXC10 can be increased through the phosphorylation of a C-terminal serine residue by CKII,
resulting in enhanced inhibition of HOX transcriptional activity, and indicating an additional layer of
regulation [34].
In addition to CK2, HOX proteins have also been shown to be substrates for cyclin-dependent
kinases (CDKs) through phosphoepitope antibody recognition and electrophoretic mobility shift
assays in Xenopus embryos. These screens revealed that HOXD1 is phosphorylated by the CDK cyclin
B-Cdc2 during mitosis [35]. Another HOX protein that undergoes post-translational modification
in a cell-cycle-dependent manner is HOXC10, which is targeted for degradation early in mitosis
by the ubiquitin-dependent proteasome pathway [36]. Notably, amongst the abdominal-B related
proteins, this property seems unique to HOXC10, as the levels of the paralogous HOXD10 and
the related HOXC13 protein were, in contrast, found to be constant throughout the cell cycle.
This HOXC10-specific activity appears to be dependent on two destruction box (D-box) motifs,
as mutating these sequences results in the stabilisation of HOXC10, and the accumulation of cells in the
metaphase. These findings indicated that HOXC10 is a prometaphase target of the anaphase-promoting
complex (APC), which is supported by the co-immunoprecipitation of HOXC10 with the APC subunit
CDC27, and its stabilisation in APC-depleted extracts. Hence HOXC10 has the potential to influence
mitotic progression and may be a link between developmental regulation and cell cycle control [36].
Although there is currently no direct experimental evidence for a role of other kinases in regulating
the cell-cycle dependent function of HOX proteins, multiple HOX family members have consensus
recognition sites for the ATM serine/threonine kinase (Figure 1). ATM is best characterised for its role
in the repair of double-stranded breaks in DNA, although it also interacts with proteins involved in
the G1/S, intra-S and G2/M checkpoints [37]. Consensus recognition sites are also present for the
functionally-related kinase ataxia telangiectasia and Rad3-related protein (ATR). ATR is activated in
response to persistent single-stranded DNA found at stalled replication forks and causes cell cycle
arrest, allowing repair to occur [38].
4. Kinase Regulation of HOX Proteins in Disease
Given the importance of the HOX genes in cancer, it is not surprising that HOX proteins are
substrates of kinases known to have pro-oncogenic roles. These include the mammalian target of
rapamycin (mTOR), a serine/threonine kinase that has a key role in cancer, promoting cellular activities
that include protein synthesis, autophagy, survival, proliferation and growth. A proteomics-based
study revealed that multiple HOX proteins (HOXA3, A5, A9, A11, B6, C4, and D11) can be
phosphorylated by mTOR at a serine or threonine residue close to the N-terminus of each protein [39].
HOX proteins also contain consensus binding sites for another protein kinase with a key oncogenic
role, PKA (Figure 1), which has been shown to have a role in the initiation and progression of multiple
tumour types [40]. In a number of HOX proteins, there is a PKA consensus site either adjacent to or
overlapping with the hexapeptide domain, indicating that PKA might also play a role in modulating
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the interactions between HOX proteins and their cofactors. Additionally, or alternatively, PKA might
increase the transcriptional activation by HOX proteins through a similar process to that identified
for the HOX co-factor MEIS1A [41], in which PKA phosphorylation increases its ability to bind the
transducer of regulated CREB activity (TORC) protein. A role for PKA in regulating HOX activity is
further supported by the observation that inhibition of PKA leads to reduced HOXD13 expression [42].
As discussed above, the disruption of HOX binding to PBX cofactors using a peptide antagonist
of this interaction (HXR9) is cytotoxic in a range of solid malignancies, primarily through the induction
of apoptosis [20]. The inhibition of HOX/PBX dimers also causes cell death in acute myeloid
leukaemia (AML), although this seems to involve necroptosis (a regulated form of necrosis), rather
than apoptosis [43]. The killing of AML cells by HXR9 is greatly enhanced by the inhibition of protein
kinase C (PKC). Although the mechanism underlying this interaction has not yet been dissected
experimentally, there are multiple PKC consensus sites in a large subset of HOX proteins, suggesting
that PKC phosphorylation might directly affect HOX function through either DNA or cofactor binding,
or stability [43]. The former is supported by the observation that HOXA9, identified as a key oncogene
in AML, is phosphorylated at S204 and T205 by PKC and that this, in turn, increases the stability of the
HOXA9/PBX/DNA complex [44].
The abundance of CKII sites in HOX proteins (Figure 3) indicates that this kinase also might
have an important role in HOX protein regulation beyond early development, including cancer.
CKII is a relative latecomer with respect to its potential as a therapeutic target, but it is known to be
over-expressed in a wide range of both solid cancers and malignancies and supports tumour growth
through regulating multiple cellular processes, including apoptosis and the cell cycle [45]. A study by
Yaron et al. showed that CKII has a role in regulating HOXB7 function in the murine myelomonocytic
cell line, 32D. Wild type HOXB7 blocks the G-CSF-induced differentiation of 32D cells, whilst HOXB7
with mutations that prevent PBX binding does not. Intriguingly, the mutation of 2 CKII sites in HOXB7
resulted in even more potent inhibition of cell differentiation compared to the wild-type protein,
indicating that CKII acts as a negative regulator of this HOXB7 function [26].
During the development of both solid tumours and haematological malignancies, the HOX genes
can form chimeric oncogenes as a result of chromosomal rearrangements at a relatively high frequency,
although chimeric HOX proteins are more common in haematological malignancies [46]. This will
clearly have profound effects on the post-translational regulation of HOX proteins as part of the protein
will be missing, and the remaining portion will be fused to a different protein subject to different
modifications. Furthermore, the chimeric protein will have a different tertiary structure that could
hide or reveal new sites. A frequent fusion partner for HOX genes is NUP98, which encodes a nuclear
membrane protein involved in the selective transport of RNA. Typically, NUP98/HOX fusions involve
the C-terminal half of the HOX partner and the approximate N-terminal two-thirds of NUP98 [47,48].
Consequently, the kinase consensus sites described above for which experimental evidence exists
(CKII and PKC) remain in the chimeric protein. In this context, it is noteworthy that both PKC [49] and
CK2 [50] inhibitors have proved effective in AML, although it remains to be determined whether AML
cells are expressing a HOX-containing chimeric protein and relatively more sensitive to these inhibitors.
5. Conclusions
There have been a number of important studies on the phosphorylation of HOX proteins that may
have been overlooked due to their somewhat disparate nature and the fact that their publication was
spread across several decades. Taken together though, the available evidence points to a significant
role for phosphorylation in the regulation of HOX transcription factors in both development and
cancer. There are also multiple, conserved kinase consensus sites in the HOX protein family which
as yet have no known function, indicating a significant gap in our current knowledge of how these
proteins regulate fundamental cellular processes.
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